CL2014001158A1 - Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. - Google Patents

Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.

Info

Publication number
CL2014001158A1
CL2014001158A1 CL2014001158A CL2014001158A CL2014001158A1 CL 2014001158 A1 CL2014001158 A1 CL 2014001158A1 CL 2014001158 A CL2014001158 A CL 2014001158A CL 2014001158 A CL2014001158 A CL 2014001158A CL 2014001158 A1 CL2014001158 A1 CL 2014001158A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
inflammation
cancer
kit
prepare
Prior art date
Application number
CL2014001158A
Other languages
English (en)
Inventor
James John Crawford
Wendy B Young
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47146780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001158(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014001158A1 publication Critical patent/CL2014001158A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2014001158A 2011-11-03 2014-05-02 Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. CL2014001158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161555395P 2011-11-03 2011-11-03

Publications (1)

Publication Number Publication Date
CL2014001158A1 true CL2014001158A1 (es) 2014-09-12

Family

ID=47146780

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001158A CL2014001158A1 (es) 2011-11-03 2014-05-02 Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.

Country Status (23)

Country Link
US (3) US8729072B2 (es)
EP (1) EP2773639B1 (es)
JP (2) JP5976828B2 (es)
KR (1) KR101716011B1 (es)
CN (1) CN104024255B (es)
AR (1) AR088642A1 (es)
AU (1) AU2012332368A1 (es)
BR (1) BR112014010439A2 (es)
CA (1) CA2853970A1 (es)
CL (1) CL2014001158A1 (es)
CO (1) CO6950475A2 (es)
CR (1) CR20140187A (es)
EA (1) EA027561B1 (es)
IL (1) IL232280A0 (es)
IN (1) IN2014CN03265A (es)
MA (1) MA35725B1 (es)
MX (1) MX2014005289A (es)
PE (1) PE20141686A1 (es)
PH (1) PH12014500966A1 (es)
SG (1) SG11201401993RA (es)
TW (1) TW201326171A (es)
WO (1) WO2013067277A1 (es)
ZA (1) ZA201403158B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782405B2 (en) 2011-11-03 2017-10-10 Genentech, Inc. Heteroaryl pyridone and aza-pyrodine compounds

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021374A2 (en) 2011-08-05 2013-02-14 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
EA027561B1 (ru) * 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
MX2015018038A (es) 2013-07-03 2016-03-16 Hoffmann La Roche Compuestos de heteroaril-piridona y aza-piridona-amida.
US9260415B2 (en) 2013-12-05 2016-02-16 Genentech, Inc. Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
JP6878004B2 (ja) 2013-12-13 2021-05-26 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
WO2016050921A1 (en) 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
CN107108604B (zh) 2014-10-27 2020-07-24 豪夫迈·罗氏有限公司 制备三环内酰胺化合物的方法
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
KR102894264B1 (ko) * 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
CN113925833A (zh) 2016-02-29 2022-01-14 豪夫迈·罗氏有限公司 包含酪氨酸蛋白激酶抑制剂的剂型组合物
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
WO2018109050A1 (en) * 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for preparing btk inhibitors
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
EP3930717A1 (en) 2019-02-25 2022-01-05 Guangzhou Lupeng Pharmaceutical Company Ltd. Inhibitor of btk and mutants thereof
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021066958A1 (en) 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP7763767B2 (ja) 2020-02-20 2025-11-04 ハチメド リミテッド ヘテロアリール複素環式化合物およびその使用
EP4138836A1 (en) * 2020-04-22 2023-03-01 Principia Biopharma Inc. Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors
WO2021254483A1 (zh) * 2020-06-18 2021-12-23 上海华汇拓医药科技有限公司 布鲁顿酪氨酸激酶抑制剂及其制备方法
KR20230104125A (ko) 2020-09-21 2023-07-07 허치슨 메디파르마 리미티드 헤테로아릴 헤테로사이클릭 화합물 및 이의 용도
WO2022094172A2 (en) 2020-10-30 2022-05-05 Newave Pharmaceutical Inc. Inhibitors of btk
CA3202745A1 (en) 2020-12-20 2022-06-23 Yi Chen Btk degrader
JP2025504938A (ja) * 2022-01-28 2025-02-19 ハチメド リミテッド ７，８－ジヒドロ－２ｈ－シクロペンタピロロピラジノン化合物の合成方法
CN119080748A (zh) * 2024-08-29 2024-12-06 中南大学 一种靶向brd7抑瘤蛋白的增稳剂及其在制备治疗实体肿瘤药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US8828902B2 (en) 2001-07-12 2014-09-09 Reaxa Limited Microencapsulated catalyst methods of preparation and method of use thereof
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
EP2297142B1 (en) 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
CA2728683C (en) 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) * 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
KR101862327B1 (ko) * 2010-05-07 2018-05-29 질레드 코네티컷 인코포레이티드 피리돈 및 아자-피리돈 화합물 및 사용 방법
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
WO2012030990A1 (en) 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridazinones, method of making, and method of use thereof
WO2012031004A1 (en) * 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
JP5859640B2 (ja) 2011-05-17 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ阻害剤
HK1197060A1 (en) 2011-08-17 2015-01-02 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EA027561B1 (ru) * 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782405B2 (en) 2011-11-03 2017-10-10 Genentech, Inc. Heteroaryl pyridone and aza-pyrodine compounds

Also Published As

Publication number Publication date
MX2014005289A (es) 2014-05-30
KR101716011B1 (ko) 2017-03-13
CA2853970A1 (en) 2013-05-10
EA201490859A1 (ru) 2014-09-30
US9115152B2 (en) 2015-08-25
JP2014532763A (ja) 2014-12-08
US8729072B2 (en) 2014-05-20
US20130116245A1 (en) 2013-05-09
CO6950475A2 (es) 2014-05-20
US8946213B2 (en) 2015-02-03
EP2773639B1 (en) 2017-04-26
PH12014500966A1 (en) 2014-06-09
ZA201403158B (en) 2017-09-27
AR088642A1 (es) 2014-06-25
TW201326171A (zh) 2013-07-01
SG11201401993RA (en) 2014-05-29
EA027561B1 (ru) 2017-08-31
IL232280A0 (en) 2014-06-30
CR20140187A (es) 2014-06-20
CN104024255A (zh) 2014-09-03
WO2013067277A1 (en) 2013-05-10
EP2773639A1 (en) 2014-09-10
BR112014010439A2 (pt) 2017-04-18
MA35725B1 (fr) 2014-12-01
AU2012332368A1 (en) 2014-05-22
US20150094302A1 (en) 2015-04-02
PE20141686A1 (es) 2014-11-08
CN104024255B (zh) 2017-01-18
JP2016028045A (ja) 2016-02-25
KR20140090227A (ko) 2014-07-16
US20140221365A1 (en) 2014-08-07
IN2014CN03265A (es) 2015-07-03
JP5976828B2 (ja) 2016-08-24

Similar Documents

Publication Publication Date Title
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
MX2015003140A (es) Formulaciones de enzalutamida.
CL2015000530A1 (es) Compuestos derivados ciclicos eter pirazol-4-il-heterociclil-carboxamida, como inhibidores de la quinasa pim; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, trastornos inmunologicos, enfermedades cardiovasculares, infeccion virica, inflamacion, trastornos del metabolismo/funcion endocrina y trastornos neurologicos.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CU20140068A7 (es) Triazolopiridinas sustituidas
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
GT201500069A (es) Piridinonas bicìclicas novedosas
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas